for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avenue Therapeutics Inc

ATXI.OQ

Latest Trade

6.19USD

Change

0.08(+1.31%)

Volume

2,022

Today's Range

6.04

 - 

6.19

52 Week Range

2.10

 - 

7.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.11
Open
6.04
Volume
2,022
3M AVG Volume
0.39
Today's High
6.19
Today's Low
6.04
52 Week High
7.95
52 Week Low
2.10
Shares Out (MIL)
16.56
Market Cap (MIL)
100.35
Forward P/E
-3.61
Dividend (Yield %)
--

Latest Developments

More

Avenue Therapeutics Q2 Loss Per Share $0.43

Avenue Therapeutics Says Second Pivotal Phase 3 Trial Of IV Tramadol Achieved Primary Endpoint

Avenue Therapeutics Q1 Loss Per Share $0.82

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Avenue Therapeutics Inc

Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in acquiring, licensing, developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol, an intravenous formulation of tramadol hydrochloride (HCl), for the management of moderate to moderately severe postoperative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31, 2016, the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.

Industry

Biotechnology & Drugs

Contact Info

2 Gansevoort St Fl 9

+1.781.6524500

http://www.avenuetx.com/

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-2.100

2019(E)

-1.680
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
7.22
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-261.77
Return on Equity (TTM)
-197.23

Latest News

Special Report: Biotech incubator taps investors through in-house brokerage

By Elizabeth Dilts, Benjamin Lesser, Carl O'Donnell and Michael Erman

BRIEF-Avenue Therapeutics Reports Q4 Loss Per Share $0.63

* AVENUE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

BRIEF-Avenue Therapeutics reports Q3 loss per share $0.30

* Avenue Therapeutics Inc reports third quarter 2017 financial results and recent corporate highlights

BRIEF-Avenue therapeutics reports Q2 loss per share $0.70

* Avenue Therapeutics reports second quarter 2017 financial results and recent corporate highlights

BRIEF-Avenue Therapeutics ic files for IPO of up to $50 mln

* Avenue Therapeutics Inc files for IPO of up to $50 million - sec filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up